GILD

Gilead Sciences, Inc. Q1 2007 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2007. Gilead Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for life-threatening diseases, primarily HIV, hepatitis, and fungal infections. The company operates in a single business segment and maintains a joint venture with Bristol-Myers Squibb Company (BMS) for the marketing of Atripla in the United States and Canada.

Key Financial Metrics

Note: The company repaid its $99.0 million term loan in March 2007. As of March 31, 2007, there were no borrowings outstanding under its $500.0 million revolving credit facility.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 48% year-over-year, driven by a 50% increase in product sales and a 39% increase in royalty revenue.
• HIV Product Sales: HIV product sales rose 56% to $705.1 million. This was led by Truvada (up 39%) and the new launch of Atripla ($190.2 million). Conversely, Viread and Emtriva sales declined 16% each due to lower volumes as patients transitioned to combination therapies.
• Royalty Revenue: Royalties increased to $180.5 million, primarily due to a 46% increase in Tamiflu royalties from Roche, reflecting higher sales in Q4 2006.
• Expense Increases: R&D expenses rose 47% to $130.1 million due to higher headcount and clinical study costs. SG&A expenses increased 17% to $166.6 million, driven by compensation costs and accelerated stock option expensing related to the Myogen acquisition.
• Margin Compression: Product gross margin decreased from 84% to 80%. This was primarily due to the product mix shift toward Atripla, where the Sustiva component carries zero gross profit for Gilead, partially offset by lower API costs.

Outlook, Risks, and Unusual Items

• Guidance: Management expects full-year 2007 product sales to grow from 2006 levels. However, they anticipate the full-year product gross margin will be lower than 2006 due to the higher mix of Atripla sales.
• Regulatory Milestones: The FDA granted priority review for ambrisentan (PAH treatment) with a target review date of June 18, 2007. The EMEA validated the MAA for ambrisentan in March 2007, triggering an $11.0 million milestone payment from GSK (recorded as deferred revenue).
• Acquisition Integration: The company is integrating Myogen, Inc. and Corus Pharma, Inc. The Myogen acquisition resulted in a $2.06 billion purchased in-process R&D expense in 2006. The purchase price allocation remains preliminary.
• Legal Proceedings: Gilead is named in various legal actions, including Medicaid pricing litigation (mostly dismissed or preliminary) and a securities class action (dismissed but appealed). A subpoena was received from the U.S. Attorney's Office regarding marketing programs for Truvada, Viread, and Emtriva.
• Tax Matters: The company adopted FIN 48 on January 1, 2007, resulting in a $14.1 million charge to accumulated deficit. The effective tax rate for Q1 2007 was 29.9%.

Investor Verification Checklist

• Verify the sustainability of HIV product sales growth given the cannibalization of Viread and Emtriva by Atripla.
• Monitor the FDA approval timeline for ambrisentan (target June 18, 2007) and its potential impact on future revenue streams.
• Assess the impact of the $1.3 billion convertible senior notes on future dilution, noting conversion triggers at $77.50 (2011 Notes) and $76.20 (2013 Notes).
• Review the status of the U.S. Attorney's Office investigation into marketing practices for key HIV products.
• Track the finalization of the Myogen purchase price allocation and potential adjustments to deferred tax assets.